Boston Scientific promotes new president of Vascular Therapies from within

NodeGuardian · 2026-02-27T10:04:05+00:00

Boston Scientific has appointed Catherine Jennings as the new president of Vascular Therapies, succeeding Jeff Mirviss, who is retiring after 28 years with the company but will remain as a senior advisor until 2026.

NodeGuardian

2026-02-27 10:04:05

Abstract generation in progress

Boston Scientific (NYSE: BSX) has appointed Catherine Jennings as the new president of Vascular Therapies, succeeding the retiring Jeff Mirviss. Jennings has been with the company for over two decades, holding various roles across peripheral vascular and interventional functions. Mirviss, who had been with Boston Scientific for 28 years, announced his retirement last August and will continue as a senior advisor until February 27, 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes